A ver si alguno puede aclarar este entuerto: ¿Como es posible que hoy mismo 6 analistas pongan precio objetivo de 41,83 para HZNP y la acción esté ahora bajando más de un 13%?
Zacks Short Term Rating on Horizon Pharma plc
As many as 7 brokerage firms have rated Horizon Pharma plc (NASDAQ:HZNP) at 1.07. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 analysts suggested buying the company. 6 analysts rated the company as a strong buy.
Horizon Pharma plc (NASDAQ:HZNP): 6 analysts have set the short term price target of Horizon Pharma plc (NASDAQ:HZNP) at $41.83. The standard deviation of short term price target has been estimated at $5.27, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 51 and $37 respectively.
Horizon Pharma plc (NASDAQ:HZNP) witnessed a decline in the market cap on Monday as its shares dropped 9.18% or 2.93 points. After the session commenced at $31.78, the stock reached the higher end at $32.34 while it hit a low of $28.73. With the volume soaring to 8,239,357 shares, the last trade was called at $28.99. The company has a 52-week high of $39.49. The company has a market cap of $4,615 million and there are 159,209,000 shares in outstanding. The 52-week low of the share price is $10.15.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Horizon Pharma Plc, Watkins Thomas had purchased shares worth of $313,200 in a transaction dated on August 19, 2015. A total of 10,000 shares were purchased at a price of $31.32 per share. The information is based on open market trades at the market prices.Option exercises are not covered. Currently the company Insiders own 0.2% of Horizon Pharma plc Company shares. In the past six months, there is a change of -5.04% in the total insider ownership. Institutional Investors own 87.5% of Company shares. During last 3 month period, 24.07% of total institutional ownership has changed in the company shares.
Many analysts have commented on the company rating. Major Brokerage house, Piper Jaffray maintains its ratings on Horizon Pharma plc (NASDAQ:HZNP). In the latest research report, Piper Jaffray raises the target price from $38 per share to $48 per share on the shares. According to the information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on July 21, 2015.
The company shares have rallied 167.56% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $39.49 and one year low was seen on October 15, 2014 at $10.15. The 50-day moving average is $30.87 and the 200 day moving average is recorded at $30.23. S&P 500 has rallied 1.82% during the last 52-weeks.
Horizon Pharma Public Limited Company, (Horizon), formerly Horizon Pharma, Inc., is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Companys other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Companys distribution partner, Mundipharma International Corporation Limited (Mundipharma). In September 2014, the Company acquired Vidara Therapeutics International plc.
HZNP
